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Abstract: Changes in DNA methylation patterns is a prominent characteristic of human tumors. Tumor cells display re-
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tion and DNMTs as key determinants of carcinogenesis is further elucidated. The chromatin modifying proteins that are 
known to interact with DNMTs are also described. Finally, the role of DNMTs as potential therapeutic targets is ad-
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1. INTRODUCTION 
  Cancer has long been viewed as a set of diseases caused 
by progressive genetic and epigenetic alterations. However, a 
large and expanding body of evidence suggests that the ini-
tiation and progression of several cancer types is controlled 
by epigenetic modifications-heritable changes in gene ex-
pression patterns that are mediated by mechanisms other 
than changes in the primary DNA sequence. Since epigenetic 
modifications are reversible, as opposed to genetic lesions, 
much research has been invested in their characterization . 
Aberrant DNA methylation is the most prominent form of 
epigenetic modification in cancer [1-3]. DNA methylation is 
caused by the covalent addition of a methyl group at the 5’ 
position of the pyrimidine ring of cytosines within the con-
text of CpG dinucleotides [4]. In human malignant cells, 
aberrant CpG methylation patterns are accompanied by ge-
nome-wide hypomethylation and gene-specific hypermethy-
lation [3, 5]. The tumor CpG methylation profiles are there-
fore useful biomarkers for cancer detection and molecular 
classification of the various cancer types. The aberrant CpG 
methylation patterns in human cancer cells are inscribed by 
the de novo DNA cytosine-5 methyltransferases (DNMTs), 
DNMT3a and DNMT3b, and transmitted in the subsequent 
cell generations by the maintenance DNMT1 [4, 6]. DNMTs 
through interactions with chromatin modifying enzymes re-
sult in a compact chromatin structure which inhibits gene 
tanscription. 
  In the current paper, a comprehensive review of CpG 
methylation, DNA methyltransferases and cancer is pre-
sented. Taking into consideration previous reports on this   
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subject, an update is provided in order to further enhance our 
understanding regarding the major epigenetic mechanism 
that contributes to carcinogenesis. The DNA methylation 
mechanism and the DNA methylation machinery are de-
scribed in detail along with the associations between 
DNMTs and chromatin modifying protein complexes.  
2. ABERRANT CpG METHYLATION PATTERNS IN 
CANCER 
  Aberrant methylation of CpG dinucleotides is an early 
event in carcinogenesis which increases in magnitude during 
tumor progression. DNA hypermethylation would mediate 
most of the important pathway anomalies in cancer including 
genetic instability, disruption of normal cell-cell interaction, 
inactivation of signal transduction cascades, loss of apoptotic 
signals etc. [7, 8]. 
2.1. CpG Island Methylation and Epigenetic Gene Silenc-
ing 
  A characteristic of the mammalian DNA methylation 
patterns is the presence of CpG islands, regions with a high 
C and G content and a frequent occurrence of CpG dinucleo-
tide clusters. CpG islands are usually positioned near the 
transcription start sites of expressed genes [9, 10]. Several 
lines of evidence suggest an inverse correlation between 
methylation of CpG dinucleotides and transcriptional gene 
regulation. How does cytosine-5 DNA methylation lead to 
transcriptional silencing?  
  According to the first mechanism, the 5-methyl cytosine 
protrudes into the major groove of the DNA double helix 
thereby preventing the binding of transcription factors or the 
basal transcriptional machinery to their recognition sites 
(Fig. 1) [11]. 
  The second mechanism that contributes to methylation-
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that selectively bind to methylated CpG dinucleotides [12]. 
These proteins include a conserved family of proteins that 
share a common motif, the methyl-CpG-binding domain 
(MBD) [13]. Four members of this family, MBD1-3 [14] and 
the mammalian methyl CpG-binding protein 2 (MeCP2) [15] 
are implicated in DNA methylation-dependent transcrip-
tional silencing [16-18]. The founding member of this fam-
ily, MeCP2, can inhibit transcription through a minimal tran-
scriptional repression domain (TRD) [19]. MeCP2 is also 
capable of binding to abundant sites both in naked DNA and 
within chromatin, as well as interacting with several regula-
tory proteins [15]. The methyl-CpG binding proteins possi-
bly cause methylation-mediated transcriptional repression by 
excluding certain transcription factors from binding to their 
recognition sites (Fig. 1).  
  Dense methylation of the CpG islands of the promoter 
regions of cancer-associated genes has been reported to lead 
to a transcriptionally inactive, compact chromatin structure 
[20]. The chromatin is organized in a compressed form, rep-
resenting an obstacle to RNA polymerase and to regulatory 
DNA-binding proteins to access the eukaryotic promoters. 
At sites where transcriptional activation occurs, this tightly 
coiled and condensed chromatin structure unfolds and the 
DNA is sensitive to cleavage by DNase I; this condensed 
chromatin structure is maintained at sites where transcription 
is repressed [21]. DNA is wrapped around an octamer of 
histone proteins, [H2A-H2B]2-[H32-H42], to form the nu-
cleosome, which is the fundamental repeating unit of chro-
matin [22]. Therefore, histone modification is a powerful 
device to unfold chromatin. Most histone modifications oc-
cur in the lysine residues in their protruding N-terminal tail 
domains which are subject to modifications, such as acetyla-
tion and methylation [23]. 
  Acetylation of histones H3 and H4 by histone acetyl-
transferases (HATs) weakens electrostatic DNA-histone in-
teractions and promotes an open chromatin conformation. 
Acetylated histone tails increase the affinity of chromatin for 
transcription factors and bromodomain-containing proteins, 
generally leading to transcriptional activation [24]. Con-
versely, deacetylation of histones by HDACs (histone deace-
tylases) strongly correlates with chromatin condensation and 
transcriptional repression [25]. The other histone modifica-
tion, histone methylation, is catalyzed by the enzyme family 
of histone methyltransferases (HMTs). Histone methylation 
can either result in transcriptional activation or repression, 
depending on the target lysine. For instance, methylation of 
histone lysines H3-K9, H3-K27 and H4-K20 generally corre-
lates with transcriptional gene silencing, whereas H3-K4, 
H3-K36 and H3-K27 methylation is usually associated with 
transcriptional gene activation [26, 27].  
  The two epigenetic processes, DNA methylation and 
chromatin modification, are dynamically linked in order to 
silence genes in cancer. As support to this notion, several 
MBD proteins are shown to be associated with histone modi-
fying complexes (Fig. 1). For example, the mammalian 
MeCP2 was shown to be associated with large protein com-
plexes containing the transcriptional co-repressor Sin3A 
which in turn binds the histone deacetylases HDAC1 and 
HDAC2 [28, 29], as well as a histone H3K9-specific HMT 
[30]. Besides, MeCP2 has been shown to be associated with 
Brahma, a catalytic domain of a SWI/SNF–like ATP-
dependent chromatin remodeling complex that disrupts 
DNA-histone interactions. This association led to transcrip-
tional inactivation [31]. Furthermore, the protein MBD2 be-
longs to the MeCP1 complex together with the HDAC1 and 
HDAC2, and two retinoblastoma-associated histone-binding 
proteins [32]. MBD3 was identified as a core component of 
the Mi2-NuRD complex, which exhibits both histone deace-
tylase and ATPase-dependent nucleosome remodeling activi-
ties. MBD2 interacts with MBD3 to recruit the Mi2-NuRD 
complex to methylated DNA [33, 34] (see Fig. 1).  
  Kaiso is another protein able to selectively bind to methyl 
CpG, although it lacks the MBD motif [35]. Kaiso is a com-
ponent of the human HDAC-containing co-repressor com-
plex, N-CoR, which resembles the Sin3 and NuRD complex 
[36, 37]. N-CoR is implicated in the transcriptional repres-
sion of a vast number of transcriptional factors [38]. The 
Kaiso/N-CoR complex was demonstrated to be able to cause 
DNA methylation-mediated transcriptional repression in-
volving both hypoacetylation and H3-K9 methylation (Fig. 
1) [39]. Furthermore, Kaiso is a member of the BTB/POZ 
family of zinc finger transcription factors, which includes the 
oncogenic proteins BCL, ETO and PLZF [40]. It would be 
intriguing to further investigate if other members of this fam-
ily have methyl-CpG binding activity.  
 
 
 
 
 
 
 
 
 
Fig. (1). Mechanisms of transcriptional inactivation by cytosine-5 methylation. The binding of transcription factors (TFs) to their cognate 
sequences is prevented by DNA methylation. Protein complexes recruited by DNA methylation establish a condensed chromatin sctructure 
which renders the template inaccessible to the cellular transcription apparatus. DNA is represented by a thick black line. The methylated 
cytosine residues are shown as filled black lollipops.  570    Current Genomics, 2010, Vol. 11, No. 8  Pavlopoulou
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  Additional proof that DNA methylation and chromatin 
modifications are functionally connected comes from the 
human ATRX [41] and the murine lymphoid-specific helicase 
2(Lsh2) genes [42], both of which encode homologues of the 
chromatin remodeling protein SNF2. Mutations in these 
genes led to diverse changes in the global DNA methylation 
patterns [41, 42]. 
2.2. A Direct Role for CpG Island Methylation in Car-
cinogenesis 
  The genome of tumor cells is characterized by profound 
alterations of DNA methylation compared to their normal 
counterparts. Whether CpG island methylation is a cause or a 
consequence of cancer is a controversial issue. The early 
occurrence of CpG methylation in several cancer types is 
suggestive of a critical role in the etiology of human cancer. 
Typically, tumor cells exhibit genome-wide CpG dinucleo-
tide hypomethylation concomitant with CpG hypermethyla-
tion of tumor suppressor and pro-apoptotic genes (Fig. 2) 
[43, 44]. 
2.2.1. CpG Island Hypermethylation in Cancer is Wide-
spread 
  Ample evidence suggests that CpG islands in the pro-
moters of various tumor suppressor genes are frequently hy-
permethylated in cancer cells resulting in gene silencing [8, 
44]. Abnormal gene silencing occurs more frequently during 
the early stages of tumorigenesis such as the precancerous 
stages of tumor development (Fig. 2) [45]. Several studies 
have reported abnormal epigenetic silencing of several genes 
during the pre-invasive stages of lung, prostate and colon 
cancer. These early epigenetic changes could predispose 
cells to genetic abnormalities that promote tumorigenesis [1].  
  Disruption of the function of a tumor-suppressor gene, 
according to Knudson’s two-hit hypothesis, requires com-
plete loss of function of both gene copies [46]. The first hit 
involves germline mutation (in familial cancer) or somatic 
mutation (in non-inherited cancers). On the contrary, the 
second hit generally involves epigenetic inactivation of the 
wild-type allele of a tumor suppressor gene by aberrant pro-
moter hypermethylation which leads to complete disruption 
of the function of the gene [47]. Hypermethylation-mediated 
gene silencing can lead to selective loss of key gene func-
tions in cancer [47, 48]. A brief list of the most important 
genes inactivated by promoter hypermethylation in cancer 
along with the cellular pathways involved is presented in 
Table 1. 
  Hypermethylated genes were identified that are shared 
within each tumor type and others that exhibited distinct 
tumor-type-specificity [5]. For example, the gene encoding 
the cyclin-dependent kinase inhibitor p16
INK4a which is re-
quired in the cyclinD-Rb pathway is disrupted in virtually all 
tumors [49]. Moreover, p53 is considered as the tumor-
suppressor gene most commonly mutated in cancer [48]. On 
the other hand, certain tumor-suppressor genes are silenced 
in different tumor types. In particular, promoter hypermethy-
lation-induced transcriptional inactivation of the BRCA1, 
RASSF1A and GSTP1 genes occurs almost exclusively in 
familial breast [50], lung [51] and prostate cancer [52], re-
spectively. In addition, hypermethylation of the estrogen-
receptor (ER) gene in ageing colorectal mucosa results in 
predisposition to sporadic colorectal carcinogenesis [53]. 
  Candidate tumor suppressor genes can be identified by 
virtue of promoter hypermethylation. According to Laird 
[54], dense hypermethylation of CpG islands provides one of 
the most promising markers for early cancer detection and 
risk assessment for the future development of disease. The 
efficiency of a biomarker assay is determined by its sensitiv-
ity (the minimal quantity of the substrate that can be de-
tected) and specificity (the percentage of assays that cor-
rectly distinguish normal from cancer-containing samples) 
[55]. The restriction landmark genomic scanning (RLGS) 
assay is one of the earliest tools that have been utilized to 
search for genome-wide aberrant CpG island methylation 
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patterns [56]. Sensitive detection of aberrant CpG methyla-
tion patterns in cancer relies on the principle of MSP (methy-
lation-specific PCR) [57] or fluorescent-based variants, such 
as MethyLight [58]. Another suitable assay for high-
throughput CpG methylation analysis in cancer is methyla-
tion-specific oligonucleotide (MSO) microarray method. 
Following bisulfite treatment and PCR amplification, the 
products are hybridized on microarrays. MSO microarray is 
able to detect methylation at specific nucleotide positions. 
Fluorescence detection is used to obtain quantitative differ-
ences [59]. 
  Prediction of response to a therapeutic treatment is an-
other potential application of CpG-island hypermethylation 
as biomarker [54]. For instance, transcriptional inactivation 
of the DNA repair genes hMLH1 and O
6-MGMT by hyper-
methylation resulted in microsatellite instability [60] and 
increased frequency of mutation rates [61], respectively ow-
ing to faulty DNA repair. O6-MGMT is responsible for re-
pairing acetylation damage to the guanine base of DNA. 
Thus, tumors with defective O6-MGMT function due to hy-
permethylation would be more sensitive to the effects of 
chemotherapy that depends on alkylating agents because of 
the diminished capacity of cancer cells to repair DNA le-
sions which leads to cell death [61].  
2.2.2. DNA Hypomethylation of Transformed Cells  
  According to Esteller [43], the degree of the undermethy-
lated genomic DNA increases through all the stages of tu-
morigenesis, from the benign proliferations to the invasive 
cancers (Fig. 2). DNA hypomethylation can contribute to 
tumorigenesis by invoking two mechanisms. The first one is 
the potentially harmful re-activation of previously silent pro-
teo-oncogenes, such as Raf, c-Myc, c-H-RAs, c-K-Ras, c-Fos 
and BCL-2 [62]. Hypomethylation of oncogenes could alle-
viate the transcriptional repression imposed by methylation 
in the promoter region of these genes and restore their ex-
pression.  
  The second mechanism by which DNA deficiency is 
suggested to play a significant causal role in oncogenesis is 
by promoting genomic and chromosomal instability. The 
main purpose of DNA methylation has been proposed to be 
genome control by repressing the transcription of parasitic 
and mobile DNA elements [63]. Undermethylation of malig-
nant cell DNA can reactivate intragenomic parasitic DNA 
elements, such as ALU and LINES [64, 65]. These and other 
normally silent transposable elements pose a threat to ge-
nomic integrity by inserting themselves into coding regions, 
disrupting the active host gene or modulating its regulated 
expression [66]. Transposons favour recombination between 
non-allelic repeats that can cause unbalanced translocations, 
deletions or isochromosome formation [64]. DNA methyla-
tion may suppress recombination either by occluding the 
recombination initiation site or by methylating the recombi-
nation-associated genes and inhibiting their transcription 
[67]. 
  DNA deficiency leads to chromosome instability, as well, 
which is the most common form of genetic instability in hu-
man cancer [68]. The maintenance of proper DNA methyla-
tion in the heterochromatin in the vicinity of the centromere 
(pericentromeric region) - the site of attachment of the mi-
totic spindle - is a prerequisite for stability and for faithful 
DNA replication [47]. DNA hypomethylation has been asso-
ciated with the rare recessive disease ICF (Immunodefi-
ciency, Centromeric instability, Facial anomalies). The most 
diagnostic feature of this disease is profound pericentromeric 
rearrangements in mitogen-stimulated lymphocytes [69, 70]. 
Similarly, some of these pericentromeric regions have been 
frequently observed in many types of cancer. In particular, it 
was found that 15-40% of breast adenocarcinomas display 
hypomethylation of the classical satellite DNA (the major 
components of the constitutive heterochromatin) at the 
pericentromeric regions along with pericentromeric rear-
rangements [71]. Chromosome instability is more pro-
nounced in stimulated thymic lymphocytes in mice, accom-
panied by extensive loss of DNA methylation; the clinical 
manifestation is combined immunodeficiency. Thymic lym-
phocytes may express factors that destabilize undermethy-
lated DNA or fail to express factors that stabilize hypometh-
ylated sequences [72, 73]. 
3. THE DNA METHYLATION MACHINERY 
  Aberrant CpG-island methylation in cancer is regulated 
by DNMT1, DNMT3A and DNMT3B which catalyze the 
transfer of a methyl moiety from the methyl donor S-
adenosyl-L-methionine to the carbon-5 of a cytosine base [4, 
6]. DNMTs consist of the catalytic C- terminal domain and 
several regulatory domains in the N terminus [6]. DNMT1 
has a preference for hemimethylated DNA and is considered 
responsible for maintaining the DNA methylation patterns 
[4, 6, 74]. DNMT3A and DNMT3B mediate de novo methy-
lation during embryogenesis and development [4, 6, 75]. 
However, this distinction of functions is not clear, since 
Table 1.  Genes Silenced by Promoter Hypermethylation 
Pathway Genes 
Cell cycle regulation and apoptosis  p53, p73, Rb, p16
INK4a, p15
INK4b, p14
ARF, HIC1, DAPK1, Caspase-8, APAF1, TMS-1 and RASSF1A 
DNA-damage repair  O
6-MGMT, hMLH1, GSTP1 and BRCA1 
Tumor-cell invasion and metastasis  TIMP-3, APC, E-cadherin, H-cadherin, LK-B1, TSP-1, THBS-1, SFRP1, and VHL  
Growth-factor response  SOCS-1, RAR, AR, ER, PR, and PRLR 
AP AF1, apoptosis-associated factor 1; APC, adenomatous polyposis coli; AR, androgen receptor; BRCA1, breast carcinoma 1; DAPK1, death-associated protein kinase 1; ER, estro-
gene receptor; GSTP1, glutathione-S-transferase P1; HIC1, hypermethylated in cancer 1; O
6-MGMT, O
6-methylguanine-DNA methyltransferase; PR, progesterone receptor; PRLR, 
prolactin receptor; RAR, retinoic acid receptor beta; RASSF1A, RAS-associated-domain family protein 1A; Rb, retinoblastoma; SFRP1, secreted frizzled-related protein 1; SOCS-1, 
suppressor of cytosine signaling-1; THBS-1, thrombospondin-1; TIMP-3, tissue inhibitor of metallopreoteinase 3; VHL, von Hippel-Lindau. 572    Current Genomics, 2010, Vol. 11, No. 8  Pavlopoulou
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DNMT3A and DNMT3B are involved in maintenance meth-
ylation [76] and DNMT1 can contribute to de novo methyla-
tion in specific cases [6, 77].  
3.1. A Direct Role for DNMTs in Tumorigenesis 
  Numerous studies implicate DNMTs in the DNA abnor-
malities in cancer. Constitutive over-expression of exoge-
nous DNMT1 in tissue culture cells was reported to induce a 
cell passage-dependent, gradual, hypermethylation of se-
lected CpG island which was accompanied by tumorigenic 
transformation [77, 78]. Moreover, overexpression of 
DNMT1 contributes to cell transformation by the fos onco-
gene [79]. Increased levels of DNMTs and activities occur in 
various types of cancer. It was shown that a reduction in the 
Dnmt1 activity due to heterozygosity or treatment of mice 
with the Dnmt1 inhibitor 5-aza-2’-deoxycytidine, reduced 
the number of intestinal polypops in mice heterozygous for 
Apc
Min, a mutation that predisposed to colonal neoplasia [80, 
81]. DNMT1 was also reported to be overexpressed in hu-
man colon cancer (several hundredfold) in comparison to 
normal colon mucosa [82]. Moreover, elevated DNMT1 pro-
tein levels were observed in MCF-7 human breast cancer 
cells compared to normal human mammary epithelial cells 
[83].  
  DNMTs can contribute to tumorigenesis through CpG 
island-hypermethylation-mediated gene inactivation. DNMT1, 
DNMT3A and DNMT3B were substantially over-expressed 
in human hepatocarcinogenesis accompanied by a marked 
increase of tumor suppressor genes methylation [84]. 
DNMT1 is thought to be responsible for most of the abnor-
mal promoter methylation in cancer cells. In particular, Rob-
ert et al. [85] demonstrated that DNMT1 was necessary and 
sufficient to maintain CpG island methylation and aberrant 
gene silencing in human cancer cells. It has been demon-
strated that DNMT1 accounts for the majority of de novo 
methyltransferase activity in protein extracts from human 
colon cancer cells [86]. Taking into account the low intrinsic 
de novo methyltransferase ability of DNMT1 cases [6, 77], 
this protein may also be capable of initiating aberrant CpG 
island methylation patterns, replacing the conventional de 
novo DNMT3s, at least in cancer cells.  
  Human cancer cells may differ in their threshold re-
quirement for DNMT1. In particular, DNMT1-deficient 
breast cancer cells were not able to maintain promoter hy-
permethylation and exhibited decreased cell viability, 
whereas colorectal and bladder cancer cells were not affected 
[87]. This differential dependence on DNMT1 in maintain-
ing cancer cell gene promoter hypermethylation and gene 
silencing may involve cooperativity between DNMTs. Ge-
netic disruption of both DNMT1 and DNMT3B resulted in 
greater than 95% reduction in genomic cytosine-5 DNA 
methylation and re-activation of silenced tumor suppressor 
genes [88]. 
3.2. DNMTs, Chromatin Remodelling, Gene Silencing 
  The amino terminus of DNMTs was shown to function as 
a transcriptional repressor through interaction with a range of 
chromatin-associated proteins. That DNMTs and chromatin 
modification are tightly associated is suggested by a study 
where the H3K9 methyltransferase ESET, which contains a 
methyl-binding domain, was shown to interact with the on-
cogenic transcription factor ERG [89]. In addition, ESET 
was found to associate with HDAC1/2 and interact with the 
transcription co-repressors mSin3A/B [90]. ESET could par-
ticipate in transcriptional regulation by methylating both 
DNA and histones and by recruiting other chromatin remod-
eling activities. 
  How are DNMTs targeted to specific regions of the ge-
nome? In leukemic cells, Dnmt1 and Dnmt3a are recruited 
by the oncogenic transcription factor PML-RAR to hyper-
methylate gene promoters. This is the first demonstration of 
recruitment of DNMTs by a transcription factor [91] (Fig. 3). 
Moreover, DNMT1 is physically associated with the retino-
blastoma (Rb) tumor suppressor gene product, and is tar-
geted to a specific gene set through its interaction with the 
sequence-specific DNA-binding factor E2F [92]. However, 
transcriptional repression by DNMT1 at an E2F-responsive 
promoter is independent of its methyltransferase activity 
[92]. Furthermore, transcriptional co-repression by Dnmt3a 
at RP58-responsive promoter does not require its de novo 
methyltransferase activity. Like other co-repressors, Dnmt3a 
associates with HDAC1 through its ATRX-homology do-
main [93] (Fig. 3). In addition, in colocteral carcinoma, his-
tone modification and silencing of p16
INK4a occurs prior to 
DNA methylation suggesting that DNA methylation serves 
as a “lock in” mechanism rather than initiator of gene silenc-
ing [94].  
  How are the transcriptionally inactive chromatin states 
maintained following DNA replication? DNMT1 was shown 
to form a complex with DMAP1 (DNMT1 associated pro-
tein) and HDAC2 [95] (Fig. 3). DMAP1 which is seques-
tered to replication foci throughout S phase by DNMT1, was 
shown to directly interact with TSG101 (tumor susceptibility 
gene 101), a transcriptional co-repressor. In contrast, 
HDAC2 was demonstrated to bind to DNMT1 only during 
late S phase. The MBD2-MBD3 complex which interacts 
with DNMT1 in the late S phase can serve as a genome-wide 
scanning apparatus which searches hemimethylated DNA 
concurrent with DNA replication. Both, DNMT1 and 
MBD2-MBD3 have been shown to interact physically with 
HDAC1 [96] (Fig. 3).  
  Histone methyltransferase-mediated DNA methylation is 
another mechanism of gene silencing in cancer cells. The 
histone methyltransferase G9a, which catalyzes the dimethy-
lation of H3K9, is considered to be responsible for the main-
tainance of transcriptionally silenced tumor suppressor gene 
promoters [97, 98]. During DNA replication, G9a through 
direct interaction with DNMT1 [99] and the DNMT1 co-
factor UHRF1 [100] coordinates the transcriptional regula-
tion of cancer-associated genes. Besides, the methylated 
H3K9- binding protein HP1 interacts with DNMT1 to medi-
ate transcriptional repression of the anti-apoptotic survivin 
gene [101]. Of considerable interest, there is a mechanistic 
link between Polycomb-mediated repression and CpG meth-
ylation. The Polycomb Repressive Complex 2 (PRC2), 
which consists of EZH2, EED and SUZ12, is necessary 
along with DNMT1 to maintain epigenetic silencing of the 
pro-apoptotic Fas gene in cancer cells [102]. EZH2 which 
catalyzes the trimethylation of H3K27 is highly expressed in 
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was found to interact directly with DNMT1 for the coordi-
nated and heritable transmission of CpG methylation pat-
terns through DNA replication [104] (Fig. 3).  
  Most of the genome contains tight, transcriptionally re-
pressive chromatin characterized by heavy CpG methylation 
and hypoacetylated histones that is replicated in late S phase. 
Thus, DNMTs and chromatin modifying enzymes could 
function in a cooperative manner for the faithful propagation 
of transcriptionally repressed chromatin states and stable 
gene silencing following cell division and DNA replication 
in cancer. In this way, it is ensured that the newly assembled 
nucleosomes are made up of densely methylated CpG 
dinucleotides and permissive histone marks; alternatively, 
deacetylase activity may be necessary to first remodel chro-
matin to allow DNMTs to carry out their methylating func-
tions.  
  Altogether, DNMTs can repress transcription independ-
ently of their ability to catalyze the methyltransferase reac-
tion. DNMTs, apart from mediating DNA methylation, can 
serve as scaffolds to direct other chromatin modifying activi-
ties to establish a transcriptionally repressed chromatin struc-
ture. 
3.3. DNMTs as Targets for Epigenetic Therapy in Cancer 
  The potential to reverse epigenetic modifications and up-
regulate genes important to prevent or reverse tumorigenesis 
has become a new therapeutic target in cancer treatment 
[105]. In particular, DNMT inhibitors have been shown to 
reactivate expression of tumor suppressor genes that have 
undergone transcriptional epigenetic silencing [106] How-
ever, a major drawback of DNMT inhibitors is that they dis-
rupt essential methylation at certain regions and they cause 
global hypermethylation which, as was discussed in the pre-
ceding section, is associated with great genomic instability. 
Another disadvantage is the toxicity to normal cells which is 
usually observed when higher doses are used [43].  
  The most extensively studied DNMT inhibitors are 5-
azacytidine (Vidaza) and its deoxy analog, 5-aza-2’-
deoxycytidine (Decitabine) which inhibit DNMTs and cause 
global hypomethylation [107]. Both are nucleoside ana-
logues replacing cytidine and 2’-deoxycytidine, respectively, 
but they contain a nitrogen in the place of pyrimidine carbon 
at the position-5. These nucleoside analogues are incorpo-
rated only into replicating DNA, and they are therefore ac-
tive only during S-phase. They serve as irreversible inhibi-
tors of DNMTs, once incorporated into DNA, since they 
form covalent complexes with DNMTs leading to the deple-
tion of active enzymes. This results in the demethylation of 
DNA in the progeny cells. 5-azacytidine is primarily acti-
vated by uridine-cytidine kinase and is partly incorporated 
into RNA, thus interfering with protein translation; 5-aza-2’-
deoxycytidine is activated by deoxycytidine kinase and is 
only incorporated into DNA, thereby causing more efficient 
inhibition of DNMTs. Both drugs have been successfully 
used in clinical trials, especially in the field of haematologi-
cal malignancies, such as myelodysplastic syndromes (MDS) 
and acute myeloid leukaemia [108, 109]. These azanucleo-
sides restored epigenetically silenced tumor suppressor 
genes, like p15
INK14, by demethylating their hypermethylated 
promoters [110]. Nevertheless, these DNMT inhibitors have 
some disadvantages. Both agents are quite toxic both in vivo 
and in vitro, and they are unstable in aqueus solution, which 
makes it difficult to administer both experimentally and 
clinically [111].  
  A chemically stable cytidine analog, zebularine [1-(beta-
D-ribofuranosyl)-1,2-dihydropyrimidin-2-one], which exhib-
its a minimal cytotoxicity both in vivo and in vitro [112] and 
a high selectivity towards cancer cells was developed [113]. 
Zebularine contains a 2-(1H)-pyrimidone ring that was ini-
tially developed as a cytidine deaminase inhibitor, because it 
lacks the amino group on position carbon-4 of the 
pyrimidine ring [114]. Similar to the two azanucleosides, 
zebularine has been demonstrated to form a tight, covalent 
bond with bacterial methyltransferases at their active site 
[115]. The agent caused complete depletion of DNMT1 and 
partial depletion of DNMT3A and DNMT3B [113].  
  Several additional inhibitors of DNMTs have been de-
scribed. The local anaesthetic procaine and its derivative 
procainamide, which is used to treat cardiac arrythmias, in-
hibit DNMTs by disturbing interactions between the proteins 
and their target sites [111]. The antihypertensive compound 
hydralazine has been shown to have demethylating activity 
which is probably attributed to the interaction between its 
nitrogen atoms and the DNMT active site [116]. In addition, 
natural products derived from green tea, epigallocatechin-3-
gallate (EGCG), and from sponges, psammaplins, have been 
shown to inhibit DNMT activity by binding to and blocking 
the active site of proteins [117].  
 
 
 
 
 
 
 
 
 
 
Fig. (3). Model for the participation of DNMTs in chromatin modification and gene silencing (see text for details). 574    Current Genomics, 2010, Vol. 11, No. 8  Pavlopoulou
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  RG108 is a small molecule that specifically fits into the 
active site of human DNMT1 and renders the enzyme inac-
tive, inducing demethylation and reactivation of tumor sup-
pressor genes, without affecting the methylation status of the 
centromeric satellite sequences. These features make RG108 
a promising candidate DNMT inhibitor, designated to block 
the active site of DNMTs and avoiding at the same time the 
adverse effects caused by global hypomethylation [118]. 
Furthermore, compounds specific for a particular DNMT 
have been developed. For instance, MG98, is an antisense 
oligonucleotide which inhibits human DNMT1 [119]. MG98 
can exert its effect by specifically hybridizing to DNMT1 
mRNA which may prevent translation, RNA transport or 
splicing. The antisense effect can be also mediated by activa-
tion of RNAseH, a ubiquitously expressed endonuclease 
which hydrolyzes the RNA strand of the heteroduplex [120]. 
  MicroRNAs (miRNAs)-non-coding RNAs of 19 to 25 
nucleotides in length that regulate gene expression through 
sequence-specific base pairing on the 3’ untranslated regions 
of target mRNA with subsequent translational inhibition or 
mRNA degradation [121]-were shown to target DNMTs. In 
particular, in lung cancer, the direct targeting of DNMT3A 
and DNMT3B by the miR-29 family was found to promote 
aberrant DNA hypomethylation and reactivation of the hy-
permethylated tumor suppressor genes FHIT and WWOX 
[122]. It was also demonstrated that miR-29b induced reex-
pression of the silenced tumor suppressor genes p15
INK4b and 
ESR1 in acute myeloid leukemia through direct targeting of 
DNMT3A and DNMT3B and indirect targeting of DNMT1 
[123]. These results, therefore, suggest a potential develop-
ment of miRNA-based approaches for efficiently targeting 
DNMTs in malignant cells.  
  As was discussed previously, there is an interdependent 
relationship between DNA methylation and chromatin modi-
fying proteins. This association between the epigenetic 
pathways encouraged the development of combinatorial 
therapies that target multiple components of the epigenetic 
machinery. It was demonstrated that DNA and HDAC in-
hibitors act synergistically to reactivate tumor suppressor 
genes [124-126]. The DNMT inhibitor 5-aza-2’-
deoxycytidine was also observed to reduce G9A and H3K9 
dimethylation levels leading to reactivation of metastatic 
suppressor genes [127]. Moreover, it was shown that HDAC 
inhibitors decreased stability of DNMT3B mRNA and 
down-regulation of de novo DNA methyltransferase activity 
in human endometrial cancer cells [128]. The HDAC inhibi-
tor depsipeptide induced reactivation of a variety of tumor 
suppressor gene promoters in lung, colon and pancreatic 
cancer cells by inhibiting expression of DNMT1 and G9a 
[129].  
4. CONCLUDING REMARKS 
  Cancer is a polyepigenetic disease. Aberrant epigenetic 
silencing of tumor suppressor genes by CpG island promoter 
hypermethylation plays an important role in the pathogenesis 
of cancer. This review has focused on DNA methylation 
aberrations and the proteins that catalyze the methylation 
process in tumor cells. The potential reversibility of CpG 
island hypermethylation and re-activation of tumor suppres-
sor and pro-apoptotic gene expression along with key control 
pathways in cancer cells presents attractive clinical possibili-
ties. DNMT inhibitors represent promising anti-tumor thera-
peutics. The tumor profiles of CpG island hypermethylation 
provide useful biomolecular markers which allow the design 
of anti-cancer drugs that specifically target certain hyper-
methylation-silenced genes. Additional studies are required 
for further unravelling the role of DNMTs in the regulation 
of cancer-relevant genes expression.  
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